文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

表达SARS-CoV-2刺突蛋白的鸡蛋基质灭活新城疫病毒疫苗的安全性和免疫原性:越南随机、安慰剂对照1/2期试验的中期结果

Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
PubMed 文献 · Vaccine · 2022-05-14

在越南河内医科大学开展的随机、剂量递增、观察者盲、安慰剂对照1/2期试验中期分析显示,18-59岁健康成人接种NDV-HXP-S疫苗后,最常见征集性不良事件主要为轻度,疫苗组疫苗相关不良事件报告比例为4%-8%,对照组为5%,未发生疫苗相关严重不良事件;10 μg配方组免疫反应最高,其次为1 μg+CpG1018、3 μg和1 μg配方;3 μg剂量与6 μg剂量一起推进至2期,10 μg剂量因可能影响生产能力未选入2期。

要点

  • NDV-HXP-S疫苗在18-59岁健康成人中安全性可接受,未发生疫苗相关严重不良事件。
  • 10 μg配方组免疫反应最高,其次为1 μg+CpG1018、3 μg和1 μg配方。
  • 3 μg剂量与6 μg剂量一起推进至2期,10 μg剂量因可能影响生产能力未选入2期。

核心结论

  • NDV-HXP-S具有可接受的安全性特征和强免疫原性;3 μg剂量与6 μg剂量一起推进至2期,10 μg剂量因可能影响生产能力未选入2期评估。
  • 由于佐剂仅显示出适度获益,1 μg±CpG1018的GMC比值为2.56(95%CI 1.4-4.6),决定不再继续研究该佐剂与本疫苗的组合。

研究设计与样本

  • 在越南河内医科大学开展的随机、剂量递增、观察者盲、安慰剂对照1/2期试验的第一阶段中期结果。
  • 2021年3月15日至4月23日筛查224人,入组120人,活性疫苗接种组每组25人,安慰剂组20人;所有受试者均接种两剂,间隔28天。
  • 受试者为18-59岁健康成人,非妊娠,自报SARS-CoV-2感染史阴性;按肌肉注射随机接受五种处理之一:1 μg±CpG1018(Toll样受体9激动剂)、单用3 μg、单用10 μg或安慰剂。
  • 主要结局为每次接种后7天内征集性不良事件和28天内受试者报告的不良事件;次要结局为免疫原性指标(抗刺突IgG和假病毒中和)。
  • 本次中期分析评估至首剂接种后56天(第57天)的安全性,以及按方案至第二剂接种后14天(第43天)的免疫原性。

主要发现

  • 接受活性疫苗或安慰剂者中最常见的征集性不良事件均主要为轻度,包括注射部位疼痛或压痛(<58%)、疲劳或不适(<22%)、头痛(<21%)和肌痛(<14%);未观察到任何活性疫苗组的征集性不良事件比例更高。
  • 疫苗组在任一次接种后28天内报告疫苗相关不良事件的比例为4%至8%,对照组为5%;未发生疫苗相关严重不良事件。
  • 第二剂接种后14天,针对同源Wuhan-Hu-1假病毒的50%中和抗体几何平均浓度(GMC)范围为56.07 IU/mL(1 μg组,95%CI 37.01-84.94)至246.19 IU/mL(10 μg组,95%CI 151.97-398.82),疫苗组中84%至96%的受试者达到较基线≥4倍升高。
  • 上述结果与一组人康复期血清(N=29,72.93,95%CI 33.00-161.14)进行了比较;对B.1.617.2(Delta)变异株的活病毒中和作用降低,但与目前使用中的疫苗观察结果一致。

关键数值与推荐

  • 10 μg配方组免疫反应最高,其次为1 μg+CpG1018、3 μg和1 μg配方。
  • 1 μg±CpG1018的GMC比值为2.56(95%CI 1.4-4.6),佐剂仅显示出适度获益。

临床怎么用

  • 3 μg剂量与6 μg剂量一起推进至2期。
  • 10 μg剂量因可能影响生产能力未选入2期评估。
  • 决定不再继续研究CpG1018佐剂与本疫苗的组合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus (NDV) vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan-Hu-1. The spike protein was stabilized and incorporated into NDV virions by removing the polybasic furin cleavage site, introducing the transmembrane domain and cytoplasmic tail of the fusion protein of NDV, and introducing six prolines for stabilization in the prefusion state. Vaccine production and clinical development was initiated in Vietnam, Thailand, and Brazil. Here the interim results from the first stage of the randomized, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial conducted at the Hanoi Medical University (Vietnam) are presented. Healthy adults aged 18-59 years, non-pregnant, and with self-reported negative history for SARS-CoV-2 infection were eligible. Participants were randomized to receive one of five treatments by intramuscular injection twice, 28 days apart: 1 μg +/- CpG1018 (a toll-like receptor 9 agonist), 3 μg alone, 10 μg alone, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited adverse events (AEs) during 7 days and subject-reported AEs during 28 days after each vaccination. Investigators further reviewed subject-reported AEs. Secondary outcomes were immunogenicity measures (anti-spike immunoglobulin G [IgG] and pseudotyped virus neutralization). This interim analysis assessed safety 56 days after first vaccination (day 57) in treatment-exposed individuals and immunogenicity through 14 days after second vaccination (day 43) per protocol. Between March 15 and April 23, 2021, 224 individuals were screened and 120 were enrolled (25 per group for active vaccination and 20 for placebo). All subjects received two doses. The most common solicited AEs among those receiving active vaccine or placebo were all predominantly mild and included injection site pain or tenderness (<58%), fatigue or malaise (<22%), headache (<21%), and myalgia (<14%). No higher proportion of the solicited AEs were observed for any group of active vaccine. The proportion reporting vaccine-related AEs during the 28 days after either vaccination ranged from 4% to 8% among vaccine groups and was 5% in controls. No vaccine-related serious adverse event occurred. The immune response in the 10 μg formulation group was highest, followed by 1 μg + CpG1018, 3 μg, and 1 μg formulations. Fourteen days after the second vaccination, the geometric mean concentrations (GMC) of 50% neutralizing antibody against the homologous Wuhan-Hu-1 pseudovirus ranged from 56.07 IU/mL (1 μg, 95% CI 37.01, 84.94) to 246.19 IU/mL (10 μg, 95% CI 151.97, 398.82), with 84% to 96% of vaccine groups attaining a ≥ 4-fold increase over baseline. This was compared to a panel of human convalescent sera (N = 29, 72.93 95% CI 33.00-161.14). Live virus neutralization to the B.1.617.2 (Delta) variant of concern was reduced but in line with observations for vaccines currently in use. Since the adjuvant has shown modest benefit, GMC ratio of 2.56 (95% CI, 1.4-4.6) for 1 μg +/- CpG1018, a decision was made not to continue studying it with this vaccine. NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 μg dose was advanced to phase 2 along with a 6 μg dose. The 10 μg dose was not selected for evaluation in phase 2 due to potential impact on manufacturing capacity. ClinicalTrials.gov NCT04830800.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Duc Dang A, Dinh Vu T, Hai Vu H, et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022. PMID: 35577631. doi:10.1016/j.vaccine.2022.04.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。